Safety and efficacy field study of artesunate for dogs with non-resectable tumours

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1819-1827

  Rutteman, Gerard R ^a,b   Erich, Suzanne A ^a   Mol, Jan A ^a   Spee, Bart ^a   Grinwis, Guy C M ^a   Fleckenstein, Lawrence ^c   London, Cheryl A ^d   Efferth, Thomas ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Veterinary Specialist Centre De Wagenrenk   (Netherlands)

^c UNIVERSITY OF IOWA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Artesunate; Cancer; Comparative oncology; Dog; Safety study

Indexed keywords

ARINATE; ARTESUNATE; DIHYDROARTEMISININ; MELOXICAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CANCER CELL CULTURE; CARDIOTOXICITY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEVER; FIELD STUDY; GASTROINTESTINAL TOXICITY; IC 50; IN VITRO STUDY; LIMIT OF DETECTION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TREATMENT DURATION;

ARTESUNATE; CANCER; COMPARATIVE ONCOLOGY; DOG; SAFETY STUDY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOG DISEASES; DOGS; LYMPHOMA; MOUTH NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84878197336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773, 2001.
2. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH and Efferth T: Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumour cells towards artesunate. PLoS ONE 2: e798, 2007.
3. Van Agtmael MA, Eggelte TA and van Boxtel CJ: Artemisinin drugs in the treatment of malaria: From medicinal herb to registered medication. Trends Pharmacol Sci 20: 199-205, 1999.
4. Yang YZ, Asawamahasakda W and Meshnick SR: Alkylation of human albumin by the antimalarial artemisinin. Biochem Pharmacol 46: 336-339, 1993. (Pubitemid 23218623)
5. Yang YZ, Little B and Meshnick SR: Alkylation of proteins by artemisinin. Effects of heme, pH, and drug structure. Biochem Pharmacol 48: 569-573, 1994.
6. Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin towards human breast cancer cells. Life Sci 70: 49-56, 2001. (Pubitemid 33130042)
7. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Häfer R, Stamminger T, Oesch F, Kaina B and Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37: 998-1009, 2004. (Pubitemid 39164582)
8. Li PCH, Lam E and Roos WP: Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 68: 4347-4351, 2008.
9. Berdelle N, Nikolova T, Quiros S, Efferth T and Kaina B: Artesunate induces oxidative DNA damage, sustained double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther 10: 2224-2233, 2011.
10. 2/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 10: 337-346, 2010.
11. 1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anti-cancer Drugs 23: 606-613, 2012.
12. Efferth T, Olbrich A and Bauer R: mRNA expression profiles for the response of human tumour cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64: 617-623, 2002.
13. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumour cell lines. Mol Pharmacol 64: 382-394, 2003. (Pubitemid 36910002)
14. Efferth T and Oesch F: Oxidative stress response of tumour cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol 68: 3-10, 2004. (Pubitemid 38746536)
15. Efferth T: Mechanistic perspectives for 1,2,4-trioxanes in anticancer therapy. Drug Resist Updates 8: 85-97, 2005.
16. Anfosso L, Efferth T, Albini A and Pfeffer U: Microarray expression profiles of angiogenesis-related genes predict tumour cell response to artemisinins. Pharmacogenomics J 6: 269-278, 2006. (Pubitemid 44137954)
17. Rasheed SAK, Efferth T, Asangani IA and Allgayer H: First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127: 1475-1485, 2010.
18. Dell'Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A and Efferth T: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumours by the antimalarial artesunate. Biochem Pharmacol 68: 2359-2366, 2004. (Pubitemid 39535108)
19. Hou J, Wang D, Zhang R and Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14: 5519-5530, 2008.
20. Du J-H, Zhang H-D, Ma Z-J and Ji K-M: Artesunate induces oncosis-like death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 65: 895-902, 2010.
21. Singh NP and Verma KB: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10: 279-280, 2002. (Pubitemid 36164142)
22. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A and Schuler G: Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol Rep 14: 1599-1603, 2005.
23. Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, Xia XA, and Li DQ: Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 6: 134-138, 2008 (in Chinese).
24. Jansen FH, Adoub I, Comoe K. J.C, De Cnodder T, Jansen N, Tschulakow A and Efferth T: First study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res 31: 4417-4422, 2011.
25. Paolini M and Khanna C: Translation of new cancer treatments from pet dogs to humans. Nature Rev 8: 147-156, 2008.
26. Affolter VK and Moore PF: Localized and dissiminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol 39: 74-83, 2002.
27. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG, and Sørenmo KU: CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Int Med 21: 121-127, 2007.
28. Schmidt BR, Glickman NW, Denocila BW, de Gortari AE and Knapp DW: Evaluation of peroxicam for the treatment of squamous cell carcinoma in dogs. J Amer Vet Med Assoc 218: 1783-1786, 2001. (Pubitemid 32520131)
29. Modiano JF, Ritte MR and Wojcieszyn, J: The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J Vet Int Med 13: 163-174, 1999.
30. Houghton AN, Meyers ML and Chapman PB: Medical treatment of metastatic melanoma. Surg Clin N Am 76: 1343-1354, 1996. (Pubitemid 27010041)
31. Teske E, van Heerde P, Rutteman GR, Kurzman I, Moore PF and MacEwen EG: Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 205: 1722-1728, 1994.
32. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, Heiffer MH and Schuster BG: Fatal neurotoxicity after arteether and arthemeter. Am J Trop Med Hyg 54: 251-259, 1994.
33. Dayan AD: Neurotoxicity and artemisinin compounds: Do the observations in animals justify limitation of clinical use? Med Trop (Mars) 58(3 Suppl): 32-37, 1998.
34. Sanofi-Aventis: Application for inclusion of artesunate/amodiaquine fixed dose combination tablets in the WHO model list of essential medicines - April 2006 - update June 2009 - September 2010. Available at: http://www.who.int/ selection-medicines/committees/expert/18/applications/Sanofi-application.pdf
35. Hellmén E: Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumour cell lines. In Vitro Cell Dev Biol 28A: 309-319, 1992.
36. Van Leeuwen IS, Hellmèn E, Cornelisse CJ, Van den Burgh B and Rutteman GR: P53 mutations in mammary tumour cell lines and corresponding tumour tissues in the dog. Anticancer Res 16: 3737-3744, 1996. (Pubitemid 27085041)
37. Zavodovskaya R, Liao AT, Jones CLR, Yip B, Chien MB, Moore PF and London CA: Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res 67: 633-641, 2006. (Pubitemid 44082173)
38. Misdorp W: The impact of pathology on the study and treatment of cancer. In: Veterinary Cancer Medicine, second edition. Theilen GH and Madewell BR (eds.). Philadelphia, Lea & Febiger, pp. 53-70, 1987.
39. Veterinary Co-operative Oncology Group: Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comparat Oncol 2: 194-213, 2004.
40. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92: 205-216, 2000.
41. Vail DM, Michels GM, Khanna C, Selting KA, London CA and the Veterinary Cooperative Oncology Group: Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - a veterinary cooperative oncology group (VCOG) consensus document. Vet Comparat Oncol 8: 28-37, 2009.
42. Naik H, Murry DJ, Kirsch LE and Fleckenstein L: Development and validation of a high-performance liquid chromatographymass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 816: 233-242, 2005. (Pubitemid 40143511)
43. Hosaya K, Muruhari S, Lato A, London CA, Couto GC and Kisseberth WC: Biological activity of dihydroartemisinin in canine osteosarcoma cell lines. Am J Vet Res 69: 519-526, 2008. (Pubitemid 351552317)
44. Yuthavong Y, Butthep P, Bunyaratvej A and Fucharoen S: Decreased sensitivity of artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin constant spring erythrocytes. J Clin Invest 83: 502-505, 1989. (Pubitemid 19061170)
45. Ferreira ID, Lopes D, Martinelli A, Ferreira C, do Rosário VE and Cravo P: In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe. Trop Med Int Health 12: 353-362, 2007. (Pubitemid 46280625)
46. Ribeiro IR and Olliaro P: Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50-53, 1998.
47. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W and White N: International Artemisinin Study Group. Artesunate combinations for treatment of malaria: Meta-analysis. Lancet 363: 9-17, 2004. (Pubitemid 38076919)
48. Gordi T and Lepist EI: Artemisinin derivatives: Toxic for laboratory animals, safe for humans? Toxicol Lett 147: 99-107, 2004. (Pubitemid 38130178)
49. Efferth T and Kaina B: Toxicity of the antimalarial artemisinin and its derivates. Crit Rev Toxicol 40: 405-421, 2010.
50. Bennett K Si Y, Steinbach T, Zhang J and Li Q: Pharmacokinetic and pharmacodynamic evaluation of intramuscular artesunate in healthy beagle dogs. Am J Trop Med Hyg 79: 36-41, 2008. (Pubitemid 351957202)
51. Li Q, Xie LH, Haeberle A, Zhang J and Weine P: The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Am J Trop Med Hyg 75: 817-826, 2006. (Pubitemid 351627524)